ArticleCancer medicine2026
Real-World Evidence on Hospitalization Costs of Pediatric Neoplasm Patients in China: Patterns, Trends, and Associated Factors From a Retrospective Cohort Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundIn China, the incidence and burden of pediatric neoplasms have been increasing, contributing to escalating healthcare expenditures and productivity losses, with hospitalization costs constituting a major component of the economic burden. However, evidence on the full spectrum of neoplasm-related hospitalization costs for pediatric patients remains limited, particularly from real-world longitudinal studies.
methodsThis retrospective multicenter cohort study (2017-2023) analyzed pediatric hospitalization data in Shanghai by integrating data from two administrative databases. The study included all children aged ≤ 18 years hospitalized with ICD-10-coded benign and malignant neoplasms and related complications. Hospitalization costs were discounted to 2023 values, converted to US dollars, and analyzed using descriptive statistics and generalized linear models (GLMs) to identify influencing factors, including socioeconomic, clinical, and hospital-related variables.
resultsAmong 688,131 pediatric hospitalizations, 13,057 (1.91%) were for neoplasms. Neoplasm patients had significantly higher care intensity and hospitalization costs than nonneoplasm patients, with malignant neoplasms incurring the highest median costs. From 2017 to 2023, total costs for neoplasm patients declined by 26.88%, driven by a 52.87% reduction in drug costs, contrasting with rising costs for nonneoplasm patients. Leukemia was the most prevalent condition, while some rare but high-cost entities, such as secondary malignant neoplasms of the respiratory and digestive organs, were among the most expensive. GLM analysis identified sex, insurance type, pathology, surgical interventions, length of stay, and hospital characteristics as significant cost drivers.
conclusionThis study provides comprehensive evidence on hospitalization cost patterns, trends, and influencing factors for pediatric neoplasms. It highlights the need for enhanced insurance coverage, early diagnosis and treatment, and equitable resource allocation to reduce disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.